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SCOTT W. WOODS7, THOMAS H. MCGLASHAN7, JIMMY LEE8, JOACHIM KLOSTERKÖTTER9, ALISON R. YUNG10,
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An accurate detection of individuals at clinical high risk (CHR) for psychosis is a prerequisite for effective preventive interventions. Several
psychometric interviews are available, but their prognostic accuracy is unknown. We conducted a prognostic accuracy meta-analysis of psy-
chometric interviews used to examine referrals to high risk services. The index test was an established CHR psychometric instrument used to
identify subjects with and without CHR (CHR1 and CHR2). The reference index was psychosis onset over time in both CHR1 and CHR2
subjects. Data were analyzed with MIDAS (STATA13). Area under the curve (AUC), summary receiver operating characteristic curves, quali-
ty assessment, likelihood ratios, Fagan’s nomogram and probability modified plots were computed. Eleven independent studies were includ-
ed, with a total of 2,519 help-seeking, predominately adult subjects (CHR1: N51,359; CHR2: N51,160) referred to high risk services. The
mean follow-up duration was 38 months. The AUC was excellent (0.90; 95% CI: 0.87-0.93), and comparable to other tests in preventive
medicine, suggesting clinical utility in subjects referred to high risk services. Meta-regression analyses revealed an effect for exposure to anti-
psychotics and no effects for type of instrument, age, gender, follow-up time, sample size, quality assessment, proportion of CHR1 subjects
in the total sample. Fagan’s nomogram indicated a low positive predictive value (5.74%) in the general non-help-seeking population. Albeit
the clear need to further improve prediction of psychosis, these findings support the use of psychometric prognostic interviews for CHR as
clinical tools for an indicated prevention in subjects seeking help at high risk services worldwide.
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Treatments for psychosis have been in wide use for nearly
half a century, yet there is little evidence that they have sub-
stantially improved outcomes (1). Therefore, indicated pre-
ventive intervention is the main paradigm yielding new
hope for impacting the course of psychosis (2). However,
this intervention requires an accurate identification of indi-
viduals at clinical high risk (CHR), that relies on the use of
accurate prognostic tools to detect psychosis as early as pos-
sible, so that its progress can be arrested and, if possible,
reversed.
Prognostic testing is commonly used in preventive medi-
cine (3). While a screening test should identify all individu-
als who may develop the disease (4), a prognostic test is
used to predict the development or not of the future disease
when a patient shows some heralding signs or symptoms.
Examples of predictive testing in somatic medicine include
fasting glucose and oral glucose tolerance test and glycated
haemoglobin to detect subjects at high risk for diabetes
(pre-diabetes or intermediate hyperglycaemia) (5). Pre-
diabetes closely resembles the CHR state, in that only about
5-10% of people per year will progress to diabetes, with the
same proportion converting back to normoglycaemia (5).
No biological tests such as those used to detect pre-dia-
betes are available in clinical psychiatry (6). Therefore, for
an indicated prevention of psychosis, prognostic testing is
usually accomplished by administration of specific psycho-
metric interviews, which assess validated CHR criteria (7).
These instruments include: the Comprehensive Assess-
ment of At Risk Mental State (CAARMS, 8,9), the Struc-
tured Interview for Psychosis-Risk Syndrome (SIPS, 10)
and the Basel Screening Instrument for Psychosis (BSIP,
11) for the assessment of “ultra-high risk” (UHR) criteria
(12); and the Bonn Scale for the Assessment of Basic Symp-
toms (BSABS, 13) and the Schizophrenia Proneness Instru-
ments (Adult version, SPI-A, 14, and Child & Youth ver-
sion, SPI-CY, 15) for the assessment of basic symptom (BS)
criteria (16).
The UHR criteria include attenuated psychotic symptoms
(APS), brief limited intermittent psychotic symptoms
(BLIPS) and trait vulnerability plus a marked decline in psy-
chosocial functioning (genetic risk and functional deteriora-
tion syndrome: GRFD). The two partially overlapping BS
criteria rely on subjectively experienced disturbances of per-
ception, thinking, language and attention (17).
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These CHR instruments show excellent reliability when
used by trained raters: the overall inter-rater agreement is
0.95 for the SIPS (18), 0.85 for the CAARMS (12) and 0.91
for the SPI-A (19). Yet, their prognostic accuracy is still
uncertain. For an ideal instrument, all subjects actually
about to develop psychosis should be classified as “at risk”
(CHR1) while those suffering from other complaints not
leading to frank psychosis should be classified as “not at
risk” (CHR2).
The prognostic accuracy of a test can be quantified by dif-
ferent measures – sensitivity (Se), specificity (Sp), summary
receiver operating characteristic (SROC) curves, area under
the curve (AUC) – whose evaluation requires follow-up not
only of CHR1 but also of CHR2 subjects. So far, no robust
meta-analysis has addressed the consistency and magnitude
of the prognostic accuracy of psychometric CHR testing,
and the few available studies reported inconsistent prognos-
tic accuracy findings (18,20). Because of this, the overall
clinical utility (i.e., predictive value) of psychometric inter-
views in help-seeking and non-help-seeking subjects is still
unknown.
Predictive values are not fixed indicators of a test perfor-
mance, but are affected by the prevalence of the condition
(4). Within help-seeking CHR1 samples, the ability of the
above psychometric instruments to identify true positives is
accumulating to 29% at 2-year follow-up (21,22) – a finding
comparable to other preventive approaches in medicine
(23). On the contrary, the predictive value and potential
clinical utility of these instruments in samples with a lower
prevalence of the condition, such as the general population,
still await results from follow-ups (24-26). Similarly, the pre-
dictive value in other samples with a variable psychosis risk,
such as unselected adolescents with psychiatric problems
(27), subjects accessing public treatment services, psychiat-
ric patients in forensic units (28), primary care patients,
genetic high risk samples, prisoners, post-partum women,
people with 22q11.2 deletion syndrome, users of high
potency cannabis, military, black ethnic minorities, refu-
gees, people with borderline personality disorders or epilep-
sy, is still largely unknown.
To overcome this lack of knowledge, we conducted the
first robust meta-analysis to examine the consistency and
magnitude of the prognostic accuracy of instruments used for
psychosis prediction, while at the same time investigating
their potential clinical utility in help-seeking samples of high




Two investigators (MC, GR) conducted a two-step litera-
ture search. At a first step, the Web of Knowledge database
was searched, incorporating both the Web of Science and
MEDLINE. The search was extended until March 2015,
including only abstracts in English. The electronic research
adopted several combinations of the following keywords:
“at risk mental state”, “psychosis risk”, “prodrome”,
“prodromal psychosis”, “ultra-high risk”, “high risk”, “help-
seeking”, “diagnostic accuracy”, “sensitivity”, “specificity”,
“psychosis prediction”, “psychosis onset”, and name of the
CHR assessment instruments. The second step involved the
use of Scopus to investigate citations of previous systematic
reviews on transition outcomes in CHR subjects and a man-
ual search of the reference lists of the retrieved articles.
Articles identified through these two steps were then
screened for the selection criteria on the basis of abstract
reading. The articles surviving this selection were assessed
for eligibility on the basis of full text reading. To achieve a
high standard of reporting, we adopted the Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) checklist
(29).
Selection criteria
Studies were eligible for inclusion if: a) they were
reported in original articles, written in English or in Ger-
man; b) they had used in the same pool of referrals an estab-
lished CHR psychometric instrument (index test); c) they
had followed up both CHR1 and CHR2 subjects for psy-
chosis onset (reference index) using established internation-
al diagnostic manuals (ICD or DSM); d) they had reported
sufficient prognostic accuracy data. With respect to this last
point, when data were not directly presented, they were
indirectly extracted from associated data. Additionally, we
contacted all corresponding authors to request additional
data when needed.
We excluded: a) abstracts, pilot datasets, reviews, articles
in a language other than English or German; b) studies in
which interviews were not conducted in the same pool of
referrals or that used an external CHR2 group of healthy
controls; c) studies with overlapping datasets. In case of
multiple publications deriving from the same study popula-
tion, we selected the article reporting the largest and most
recent data set. The literature search was summarized
according to PRISMA guidelines (30).
Recorded variables
Data extraction was independently performed by two
investigators (MC, GR). Data included author, year of publi-
cation, characteristics of subject samples (baseline sample
sizes, mean age and age range, proportion of females), the
CHR psychometric instrument used, exposure to antipsy-
chotics, diagnostic criteria used at follow-ups to assess the
psychotic outcome, follow-up time, prognostic accuracy
data (number of true and false positives, true and false nega-
tives or associated data) and quality assessment conducted
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with the Quality Assessment of Diagnostic Accuracy Stud-
ies (QUADAS) checklist (31).
Statistical analysis
The statistical analysis followed the Cochrane Guidelines
for Systematic Reviews of Diagnostic Test Accuracy, Ver-
sion 1.0 (32) and the Methods Guide for Authors of System-
atic Reviews of Medical Tests by the Agency for Healthcare
Research and Quality (chapter 8) (33). Evaluating test accu-
racy requires knowledge of two quantities: the test’s Se and
Sp. Meta-analysis methods for diagnostic test accuracy thus
have to deal with two summary statistics simultaneously
rather than one (32). Methods for undertaking analyses
which account for both Se and Sp, the relationship between
them, and the heterogeneity in test accuracy, require fitting
advanced hierarchical random effects models (32).
For each study we constructed a two-by-two table, which
included true positive, false positive, true negative, and false
negative values. When studies reported different data at dif-
ferent follow-up times, we used data from the longest
follow-up. The baseline sample size was conservatively used
as the base reference to avoid a bias towards overly high
transition risks at longer follow-ups and related higher
drop-out rates of transition negatives.
Data were then analyzed with MIDAS (Meta-analytical
Integration of Diagnostic Accuracy Studies) (34), a compre-
hensive program of statistical and graphical routines for
undertaking meta-analysis of diagnostic/prognostic test
performance in STATA 13 software. The index tests of CHR
status (CHR1 or CHR2) and reference tests of transition to
psychosis according to international diagnostic manuals
(ICD or DSM as gold standard) were dichotomous.
Primary data synthesis was performed within the bivariate
mixed-effects regression framework for the logit transforms
of Se and Sp (34). In addition to accounting for study size,
the bivariate model estimates and incorporates the intrinsic
negative correlation that may arise between Se and Sp within
studies (threshold effect) (35), as a result of differences in the
test threshold between studies (36). The bivariate model
allows for heterogeneity beyond chance as a result of clinical
and methodological differences between studies (36).
We estimated the summary Se and Sp and the estimated
hierarchical SROC curves (32). A SROC graph across each
predictor, with the y-axis representing the predictor’s Se
and the x-axis representing 1-specificity, was used to plot
around the summary estimates a 95% confidence region
and a 95% prediction region to illustrate the precision with
which the summary values were estimated (confidence
ellipse of a mean), and to show the amount of between-
study variation (prediction ellipse; the likely range of values
for a new study). We also estimated the AUC. Finally, for
sensitivity analyses of the impact of follow-up times, supple-
mentary analyses were conducted by grouping the data at
each specific time point of 6, 12, 24 and30 months.
Heterogeneity across studies was assessed using the I2,
with values of 25%, 50% and 75% representing mild, moder-
ate and severe inconsistency, respectively (37). Within
MIDAS, forest plots and heterogeneity statistics can be creat-
ed for each test performance parameter individually or may
be displayed as paired plots. Subgroups analyses and meta-
regressions were used to examine the influence of CHR
instruments used, mean age, gender (% females), follow-up
time, sample size, exposure to antipsychotics, and quality
assessment (QUADAS) on meta-analytical estimates. To
control for biases associated with imbalanced datasets (38),
we further tested the impact of the proportion of CHR1 sub-
jects in the overall samples. The meta-regressions were used
if there was substantial heterogeneity (I2>50%) (39).
Model diagnostic analyses included quantile plot of resid-
ual based goodness-of-fit; chi-squared probability plot of
squared Mahalanobis distances for assessment of the bivari-
ate normality assumption; spike plot for checking for partic-
ularly influential observations using Cook’s distance; a
scatter plot for checking for outliers using standardized pre-
dicted random effects (standardized level-2 residuals) (34).
Sensitivity analyses (i.e., exclusion of outliers and rerunning
of the model) were conducted to further explore heterogene-
ity. We did not test publication bias (40), because no proven
statistical method exists for this type of meta-analysis (41).
In a second step, we employed the probability-modifying
plot and the Fagan’s nomogram to estimate the clinical or
patient-relevant utility of the CHR interview in subjects
seeking help at early detection services, in the general popu-
lation, as well as in other samples (i.e., genetic high risk sam-
ples, prisoners, post-partum women, people with 22q11.2
deletion syndrome, users of high potency cannabis, military,
black ethnic minorities, people with borderline personality
disorders, and unselected psychiatric samples).
The clinical utility was evaluated using the positive and
negative likelihood ratios (LR1 and LR2) to calculate post-
test probability (PostTP) based on Bayes’ theorem (with
pre-test probability, PrePT, being the prevalence of the con-
dition in the target population), as follows: PostTP5LR 3
PreTP/[(12PreTP) 1 (PreTP 3 LR)] (35). Specifically, the
probability-modifying plot (34) is a graphical sensitivity
analysis of the test’s predictive values across a baseline psy-
chosis risk continuum in people seeking help at early detec-
tion services. It depicts separate curves for positive and neg-
ative tests and uses general summary statistics (i.e., uncondi-
tional positive and negative predictive values, NPV and
PPV, which permit underlying psychosis risk heterogeneity)
to evaluate the effect of the CHR assessment on predictive
values (42). The PreTP probability of psychosis risk in sub-
jects seeking help at early detection services was computed
in the current dataset as the proportion of subjects develop-
ing psychosis on the total baseline sample (CHR1 plus
CHR2) (34).
Fagan’s nomogram, a two-dimensional graphical tool for
estimating how much the result of a test changes the pre-test
probability that a patient will develop psychosis, was used
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to estimate the clinical value of psychometric CHR inter-
view in the general population and in the other samples.
Again, the clinical value is calculated on the LR1 and LR2
obtained from the current meta-analysis (43) and using the
pre-test psychosis risk in the different samples as estimated
from the available literature.
Statistical tests were two-sided and statistical significance
was defined as p values<0.05.
RESULTS
Database
The literature review (PRISMA flow chart available from
the authors upon request) produced eleven independent
studies that met the inclusion criteria, for a total of 2,519
subjects (CHR1: N51,359; CHR2: N51,160) referred to
high risk services (Table 1). The proportion of CHR1 sub-
jects in the total sample was 0.54%, revealing an overall bal-
anced dataset.
Four studies employed the CAARMS, three the SIPS, one
the BSIP, one the BSABS, and two both the SIPS and the
SPI-A. The mean follow-up time was 37.72 months (SD
27.81, median533). QUADAS ratings ranged from 2.5 to 14
(the latter is the highest possible score). The main reasons
for a non-optimal rating were (partial) exposure to antipsy-
chotics and unsatisfactory reporting of results.
Prognostic accuracy of CHR interview
Across the eleven studies interviewing help-seeking subjects
for CHR symptoms, the summary meta-analytical estimate of
Se and the AUC were outstanding, while the estimate of Sp
was poor (Figure 1). There was moderate to substantial hetero-
geneity for Se (I2551, p50.02) and severe heterogeneity for Sp
(I2595, p<0.001), 17% of which was due to threshold effects.
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QUADAS – Quality Assessment of Diagnostic Accuracy Studies checklist, CHR – clinical high risk, UHR – ultra-high risk, BS – basic symptoms, BSABS – Bonn
Scale for the Assessment of Basic Symptoms, BPRS – Brief Psychiatric Rating Scale, BSIP – Basel Screening Instrument for Psychosis, CAARMS – Comprehensive
Assessment of At Risk Mental State, SIPS – Structured Interview for Prodromal Syndromes, SPI-A – Schizophrenia Proneness Instrument, NA – not available
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Sensitivity analyses revealed that the two studies with the
highest proportion of CHR2 subjects in the total sample
had the highest Sp (44,45), while the two studies with the
lowest proportion of CHR2 subjects had the lowest Sp
(46,47). However, meta-regression analyses showed that
the proportion of CHR1 subjects in the total sample had no
impact on the overall AUC (38).
Across SIPS samples (20,46,48-50), Se was 0.96 (95% CI:
0.88-0.99) and Sp was 0.39 (95% CI: 0.32-0.46). Across
CAARMS samples (44,45,47,51), Se was 0.96 (95% CI:
0.82-0.99) and Sp was 0.56 (95% CI: 0.38-0.73). There were
not enough data to perform subgroups meta-analyses in
BSIP samples (11), BSABS/SPI-A samples (46,50,52) and
samples combining the SIPS and SPI-A (46).
Meta-regression analyses revealed no significant effects
for mean age, gender, follow-up time, sample size and quali-
ty assessment (QUADAS), but there was a significant effect
for exposure to antipsychotics at baseline (p50.04). This
effect was driven by a significant decrease of Se (0.94) in the
five studies where subjects were exposed to antipsychotics
as compared to the six studies where subjects were not
exposed (Se50.98).
Model diagnostics revealed a good fit of the model and
indicated that one study was close to the outlier threshold
(44). Sensitivity analyses confirmed a very good AUC (0.84)
after this study was removed from the dataset.
Supplementary analyses were conducted grouping the
available samples at specific time points of 6, 12, 24 and
30 months. The AUCs were outstanding at each time
point: at 6 months (seven samples, AUC50.97, 95% CI:
0.95-0.98), at 12 months (six samples, AUC50.94, 95% CI:
0.92-0.96), at 24 months (eight samples, AUC50.94, 95%
CI: 0.92-0.96), and at 30 months (seven samples,
AUC50.91, 95% CI: 0.88-0.93).
Clinical utility of psychometric CHR interviews in
subjects seeking help at high risk services
The 38-month psychosis risk in the 2,519 help-seeking
subjects was 15% (95% CI: 0.9%-24%). On the basis of this
prior distribution, the continuous relationship between
PreTP and PostTP probability is summarized in Figure 2.
Being CHR1 was associated with a 26% (95% CI: 23%-
30%) risk of developing psychosis within 38 months, yet a
small LR1 of just 1.82 (95% CI: 1.52-2.18), while being
CHR2 was associated with a 1.56% (95% CI: 0.7%-2.42%)
risk of developing psychosis and a large LR2 of 0.09 (CI
95%: 0.04-0.18) (Figure 3).
Estimated clinical utility of psychometric CHR interviews
in the general population and in other samples
Based on a lifetime prevalence of all non-organic psy-
chotic disorders of 3.27% (53) and the above LRs, Fagan’s
Figure 1 Meta-analytical summary receiver operating characteristic
(SROC) curve of clinical high risk (CHR) psychometric interviews.
Se – sensitivity, Sp – specificity, AUC – area under the curve, 1 –
Klosterk€otter et al (52), 2 – Yung et al (45), 3 – Riecher-R€ossler et al
(11), 4 – Woods et al (20), 5 – Addington et al (48), 6 – Liu et al (49); 7
– Simon et al (50), 8 – Lee et al (44), 9 – Schultze-Lutter et al (46), 10 –
Kotlicka-Antczak et al (47), 11 – Spada et al (51)
Figure 2 Meta-analytical probability modifying plot, illustrating the rela-
tionship between pre-test probability (PreTP) (9 to 24% psychosis risk at
38 months in subjects seeking help at early detection services) and post-
test probability (PostTP) (psychosis risk at 38 months in help-seeking
subjects based on clinical high risk psychometric interviews), computed
as the likelihood of a positive (above diagonal line; LR1) or negative
(below diagonal line, LR2) test result over the 0-1 range of PreTP
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nomogram revealed only limited clinical utility for CHR
instruments in the general population. Testing positive for
CHR was associated with a 5.74% lifetime risk of develop-
ing psychosis, while testing negative was associated with
hardly any such risk (0.26%). Corresponding figures for oth-
er clinical and non-clinical samples are displayed in Table 2.
DISCUSSION
This is the first study to present a robust and elaborated
meta-analytical estimate of the prognostic accuracy of CHR
psychometric interviews for psychosis prediction. Assessing
help-seekers referred to a high risk service with a CHR
interview generally revealed an excellent overall prognostic
performance in terms of the AUC at 38-month follow-up
(values of 0.9-1.0 are considered outstanding, of 0.8-0.9
excellent and of 0.7-0.8 acceptable) (66), which is compara-
ble to other preventive approaches in medicine. However,
excellent AUC values were mainly mediated by an outstand-
ing ability of the instruments to rule out psychosis (i.e., very
satisfyingly low LR2 and high Se), at an expense of their
ability to rule in psychosis (i.e., unsatisfactory low LR1 and
only moderate overall Sp), which indicates some need to
further improve prediction. On the contrary, the clinical
utility of current CHR instruments in non-help-seeking sub-
jects in the general population was estimated to be low.
Our first aim was to investigate at meta-analytical level
the overall prognostic accuracy of CHR instruments in
determining the risk of developing psychosis at 38 months
in young help-seeking subjects referred to high risk services.
We first estimated the AUC, which serves as a global mea-
sure of test performance and indicates the overall goodness
Figure 3 Fagan’s nomogram illustrating the meta-analytical clinical
value (post-test probability) of clinical high risk (CHR) psychometric
interviews in the general population in order to predict risk of psy-
chosis at 38 months, given an assumed psychosis risk (pre-test proba-
bility) of 3.27%, as reported in a nationally representative sample of
general population subjects aged 30-44 years (see 53)
Table 2 Estimated clinical utility of clinical high risk psychometric instruments for psychosis prediction in various populations
Sample Psychosis risk Positive test result Negative test result
Unselected psychiatric adolescents (27) 3.13% (12 mo.) 3.13% 0.29%
Subjects in contact with public treatment
services (54)
0.35% (lifetime) 0.63% <0.001%
Psychiatric patients in forensic units (55) 74% (lifetime) 83.38% 20.39%
Primary care patients (56) 0.045% (per year) <0.001% <0.001%
Prisoners (57) 3.90% (lifetime) 6.87% 0.36%
Post-partum women (58) 4% (12 mo.) 7.04% 0.37%
22q11.2 deletion syndrome (59) 16% (48 mo.) 25.74% 1.68%
Young adults at familial risk for psychosis (60) 12% (30 mo.) 19.88% 1.21%
Users of high potency cannabis (61) 24% (lifetime) 36.49% 2.76%
Military (62) 0.014% (per year) <0.001% <0.001%
Black ethnic minority (63) 1.45% (lifetime) 2.60% 0.13%
Refugees (64) 3.3% (lifetime) 5.84% 0.31%
Epilepsy (65) 5.6% (lifetime) 9.74% 0.53%
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of a diagnostic tests. Thereby, we adopted a robust method-
ological approach following international guidelines for
diagnostic/prognostic accuracy meta-analysis, to avoid the
serious flaws observed in a previous meta-analytical at-
tempt, such as overlapping samples, missing studies and
lack of control for several moderators (67,68). Our finding
of consistent prognostic accuracy across CHR instruments
is particularly important, given the significant differences in
their criteria (69). This evidence of a negligible role of the
CHR assessment instrument (i.e., CAARMS vs. SIPS) is in
line with our previous meta-analysis, which found no differ-
ences in pooled annual transition risks between these
instruments (21). This finding was also confirmed by a sec-
ond independent meta-analysis (22).
We further revealed that, despite an excellent overall prog-
nostic accuracy, there is a need to specifically improve the
ability to rule in subsequent psychosis, i.e., to improve LR1
and Sp, while preserving the outstanding ability to rule it out.
This is particularly relevant given that interviewing subjects
seeking help at high risk services is particularly difficult: these
individuals are assumed to lay on an upper mid-range of a
symptomatic continuum by showing mild and often infre-
quent symptoms of yet some clinical significance already (24).
However, differentiating between such gradual symp-
toms with specific tests or interviews is not a problem spe-
cific to psychosis prevention or other preventive approaches
in psychiatry. For example, in case of the at-risk state of
diabetes, the World Health Organization (WHO) proposed
the use of the term “intermediate hyperglycaemia” (i.e., pre-
diabetes) to accurately reflect the observation that glycae-
mia is a continuous variable and that their defined catego-
ries are based on somewhat arbitrary decisions on where to
draw a line between normality and abnormality (70). Simi-
larly to the different cut-offs and criteria used to identify
CHR subjects, the definition of pre-diabetes is based on cut-
off points for glycaemia (5) for which there are different
operationalizations (e.g., by WHO and by the American
Diabetes Association) (5). Furthermore, as for the CHR
state (7), progression to diabetes is not inevitable in pre-
diabetes; some individuals, in the absence of any interven-
tion, may remain in that state or even revert to normogly-
caemia (5). Because of this, various risk assessment tools
based on socio-demographic or questionnaire data are
available to identify subjects with pre-diabetes, and their
overall prognostic accuracy is comparable to our meta-
analytical estimates, such as the AUC50.76 reported for the
Cambridge risk score (71). More broadly, the overall prog-
nostic accuracy of the CHR instruments was comparable if
not superior to various other medical tests used for an indi-
cated prevention (Table 3).
However, it is important to highlight that the high AUC
of CHR instruments is secondary to an accurate training of
raters and ongoing close supervision provided by expert
clinicians (7). Thus, a recent guidance on the early detection
Table 3 Prognostic accuracy of indicated prevention tests in clinical medicine
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Assessment Scale-cognitive part
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of psychosis explicitly recommends CHR assessment to be
conducted in specialized centres by well-trained raters and/
or clinical supervision by such raters (22).
The imbalance between an excellent Se (0.96) and an
only modest Sp (0.47) may have some relevant clinical
implications, when considering that we have selectively
included only studies discriminating CHR1 from CHR2
within the same pool of help-seeking subjects. Since these
patients were seeking help at or were subsequently referred
to early detection services and frequently presented also
with psychosocial and functional impairment (81) and oth-
er non-psychotic symptoms (82) and disorders (83), the use
of CHR assessments should not be thought of as identifying
and treating an unselected and asymptomatic group at risk
of a poor outcome (universal prevention) (84). Rather, the
use of CHR assessment follows the approach of an indicated
prevention, which is concerned with detecting a disease in
its earliest stages, before frank symptoms appear, and with
intervening to slow or stop its progression into the full-
blown medical picture. Therefore, the above-mentioned
recent guidance explicitly restricts CHR assessment to the
clients of mental health services (22).
With regard to the potential CHR1 misdiagnosis of per-
sons who do not in fact develop psychosis, or the potential
CHR2 misdiagnosis of persons who will develop psychosis,
the low Sp suggests a stepped and multi-component strate-
gy. In a first sensitivity-preserving step, CHR instruments
could be used to rule out true negatives, i.e. subjects who are
unlikely to develop psychosis. In a second step, additional
clinical, neurocognitive, biological or combined models of
risk stratification could be applied to the CHR1 group, with
the aim of increasing Sp and prognostic reliability. This
would enable risk stratification and personalized treatments
accordingly (85,86).
We further estimated the clinical utility of CHR assess-
ments in other clinical and non-clinical populations, as clini-
cal utility is affected by the underlying psychosis risk in a
population. We found that testing positive for CHR was
associated with a 26% risk of developing psychosis within 38
months, a proportion comparable with our previous meta-
analysis (95% CI: 23-35) (21) of transition risks in CHR1
subjects. This was due to a small LR1 of 1.82. We could also
show here for the first time that being CHR2 was associated
with only a 1.56% risk of developing the illness, correspond-
ing to a large LR2 of 0.09. It is important to note that the
PostTP, as estimated from the likelihood ratio and PreTP, is
generally more accurate than if estimated from the PPV of
the test. In fact, with the help of these two measures (LR1
and LR2), it was possible to estimate the PostTP in different
settings characterized by a variable PrePT of psychosis risk,
which however will still require empirical studies.
We clearly estimated for the first time a limited clinical
utility of CHR interviews in the general population, reveal-
ing only a small and inadequate PPV of 5.74%. This estimate
is in line with meta-analytical results indicating that self-
reported psychotic-like experiences in the young non-
help-seeking general population are associated with a negli-
gible risk of transitioning to psychotic disorders over time
(87). Yet, as self-reported psychotic experiences are only a
poor estimate of clinician-assessed CHR symptoms, these
findings might not reflect the true predictive power of CHR
criteria in the community. Similarly, it appears there is no
scope to use psychometric CHR interviews in unselected
psychiatric adolescent samples, patients accessing public
treatment or primary care services, patients admitted to
forensic units, post-partum women, ethnic minorities, mili-
tary, refugees, patients with epilepsy and prisoners. The lat-
ter finding is in line with a recent study indicating that the
CHR state does not predict psychosis in adolescent delin-
quent samples (28). On the other hand, our estimates pro-
vide some support for the clinical utility of CHR assess-
ments in subjects with two psychotic relatives, in patients
with 22q11.2 deletion syndrome and in subjects using high
potency cannabis, as well as for preventive trials already
proposed in some of these clinical samples (88).
The additional novel finding is that our probability-mod-
ifying plot allows future power calculation studies in sam-
ples characterized by an underlying variable psychosis risk
that is ranging from 0 to 1. For example, with our plot
available, researchers may draw a vertical line from the
selected pre-test probability of the sample to the appropri-
ate likelihood ratio line and then read the post-test proba-
bility off the vertical scale.
Some limitations of this meta-analysis should be ac-
knowledged. First, because of the limited statistical power,
we were unable to directly compare the prognostic accuracy
of different psychometric instruments. However, subgroups
analyses revealed comparable SIPS vs. CAARMS AUCs.
Furthermore, two independent meta-analyses (21,22) did
not reveal any significant impact of the type of psychomet-
ric instrument employed on risk estimates. Also, we were
unable to explain all the observed heterogeneity across indi-
vidual studies. However, some of this was accounted for by
threshold effects and the effect of antipsychotics exposure
on Se. An effect of age, with lower transition risks in youn-
ger CHR1 subjects, was observed in our first meta-analysis
(21) and recently confirmed in another re-analysis (22).
Such an age effect might have been missed in our analyses,
as only the by far smallest of the included studies, with an
only 6-month follow-up (69), was on minors only.
Furthermore, the individual studies included here varied
with respect to follow-up time, although meta-regression
did not reveal any significant effect of this variable. We addi-
tionally conducted supplementary analyses at each specific
time point, and these analyses confirmed excellent AUCs.
Furthermore, there is new meta-analytical evidence that, in
UHR samples, transition to psychosis is most likely to occur
within the first 2 years after presentation to clinical services,
with a stable plateau after 36 months (89). Since our mean
follow-up time (38 months) falls in this plateau period,
follow-up had no significant impact on the meta-analytical
estimates across samples mainly at risk for UHR criteria.
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CONCLUSIONS
The present prognostic accuracy meta-analysis indicated
that currently used interviews for psychosis prediction have
an excellent overall prognostic performance. This supports
their use as clinical tools for an indicated prevention in sub-
jects seeking help at mental health services worldwide, pro-
vided raters have undergone adequate training, while dis-
couraging their use for prevention in non-help-seeking sub-
jects in the general population.
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